Clinical significance of major and minor bcr/abl chimeric transcripts in essential thrombocythemia

Japanese Journal of Clinical Oncology

Volumn 30, Issue 11, 2000, Pages 472-477

  Yamada, Hironori ^a   Murakami, Takaya ^a   Kaneda, Tsuguhiro ^a   Tadachi, Mayumi ^a   Utsumi, Makoto ^a   Minami, Saburo ^b   Hamaguchi, Motohiro ^b   Kasai, Masanobu ^b   Kodera, Yoshihisa ^b   Ohashi, Haruhiko ^c   Morishita, Yoshihisa ^d   Terasawa, Teruhiko ^a   Yamasaki, Yumiko ^a   Kamiya, Yoshikazu ^a   Hattori, Mamiko ^a   Yamanaka, Katsuo ^a   Tsushita, Keitaro ^a   Shimoyama, Masanori ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d Aichi Prefectural Welfare Federation of Agricultural Cooperatives   (Japan)

Author keywords

Essential thrombocythemia; Gene sequence; Major bcr abl; Minor bcr abl; RT PCR

Indexed keywords

BCR ABL PROTEIN; DNA;

ADULT; AGED; ARTICLE; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; SEQUENCE ANALYSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0034524187     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyd122     Document Type: Article

References (22)

1. Evidence for a multistep pathogenesis of chronic myelogenous leukemia
2. A large proportion of patients with a diagnosis of essential thrombocythemia do not have clonal disorder and may be at lower risk of thrombotic complications
3. Essential thrombocythemia and the Philadelphia chromosome
4. Molecular analysis of Philadelphia positive essential thrombocythemia
5. Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome
6. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients: Clinical presentation
7. Might essential thrombocythemia carry Ph anomaly?
8. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
9. The presence of typical and atypical bcr/abl fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
10. Essential thrombocythemia: An interim report from the Polycythemia Vera Study Group
11. A novel leukemia cell line, MR-87, with positive Philadelphia chromosome and negative breakpoint cluster region rearrangement coexpressing myeloid and early B-cell markers
12. Rapid detection of chimeric bcr/abl mRNAs in acute lymphoblastic and chronic myeloid leukemia by the polymerase acute lymphoblastic and chronic myeloid leukemia by the polymerase chain reaction
13. Detection of major and minor bcr/abl fusion gene transcripts in a patient with acute undifferentiated leukemia secondary to treatment with an alkylating agent
14. Utility of molecular genetic analysis of bcr/rearrangement in the diagnosis of chronic myeloid leukemia
15. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myeloid leukemia be used in clinical decision making?
16. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia
17. Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: A study of 64 patients
18. Detection of residual leukemia more than 10 years after allogeneic bone marrow transplantation for chronic myeloid leukaemia
19. Clinical decision making in chronic myeloid leukemia based on polymerase chain reaction analysis of minimal residual disease
20. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making
21. Patients with essential thrombocythemia do not express bcr/abl transcripts
22. Acquisition of the Ph chromosome and BCR-ABL fusion product in AML-M2 and t(8;21) leukemia: Cytogenetic and FISH evidence for a late event